Quest for the right Drug

|
עמוד הבית / פרופס / מידע מעלון לרופא

פרופס PROPESS (DINOPROSTONE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

וגינלי : VAGINAL

צורת מינון:

התקן תוך נרתיקי : PESSARY

Posology : מינונים

4.2 Posology and method of administration
PROPESS should only be administered by qualified healthcare personnel in hospitals and clinics with specialised obstetric units with facilities for continuous fetal and uterine monitoring.
After insertion, uterine activity and fetal condition must be carefully and regularly monitored.
Posology
One vaginal delivery system is administered high into the posterior vaginal fornix.
The vaginal delivery system should be removed after 24 hours irrespective of whether cervical ripening has been achieved.
A dosing interval of at least 30 minutes is recommended for the sequential use of oxytocin following the removal of the vaginal delivery system. Only one application of PROPESS is recommended.
Paediatric population
The safety and efficacy of PROPESS in pregnant woman aged less than 18 years has not been established. No data are available.
Method of administration
Administration
PROPESS should be removed from the freezer just prior to the insertion.
No thawing is required prior to use.
There is a “tear mark” on side of the foil sachet. Open the package along the tear mark across the top of the sachet. Do not use scissors or other sharp objects which may cut the retrieval system.
The vaginal delivery system should be inserted high into the posterior vaginal fornix using only small amounts of water soluble lubricants to aid insertion. After the vaginal delivery system has been inserted, the withdrawal tape may be cut with scissors always ensuring there is sufficient tape outside the vagina to allow removal. No attempt should be made to tuck the end of the tape into the vagina as this may make retrieval more difficult.
The patient should be recumbent for 20 minutes to 30 minutes after insertion. As dinoprostone will be released continuously over a period of 24 hours, it is important to monitor uterine contractions and fetal condition at frequent regular intervals.
Removal
The vaginal delivery system can be removed quickly and easily by gentle traction on the retrieval tape.
It is necessary to remove the vaginal delivery system to terminate drug administration when cervical ripening is judged to be complete or for any of the reasons listed below.

1. Onset of labour. For the purposes of induction of labour with PROPESS, the onset of labour is defined as the presence of regular painful uterine contractions occurring every 3 minutes irrespective of any cervical change.
There are two important points to note:
(i)         Once regular, painful contractions have been established with PROPESS they will not reduce in frequency or intensity as long as PROPESS remains in situ because dinoprostone is still being administered.
(ii)        Patients, particularly multigravida, may develop regular painful contractions without any apparent cervical change. Effacement and dilatation of the cervix may not occur until uterine activity is established. Because of this, once regular painful uterine activity is established with PROPESS in-situ, the vaginal delivery system should be removed irrespective of cervical state to avoid the risk of uterine hyperstimulation.
2.     Spontaneous rupture of the membranes or amniotomy.
3.     Any suggestion of uterine hyperstimulation or hypertonic uterine contractions.
4.     Evidence of fetal distress.
5.     Evidence of maternal systemic adverse dinoprostone effects such as nausea, vomiting, hypotension or tachycardia.
6.     At least 30 minutes prior to starting an intravenous infusion of oxytocin, as there is a much greater risk of hyperstimulation if the dinoprostone source is not removed before administration of oxytocin.

The opening on one side of the retrieval device is present only to allow the manufacturer to enclose the vaginal delivery system into the retrieval device during manufacture. The vaginal delivery system should NEVER be removed from the retrieval device.
Upon removal of the product from the vagina, the vaginal delivery system will have swollen to 2-3 times its original size and be pliable.
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/2000
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

FERRING PHARMACEUTICALS LTD

רישום

131 89 29517 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

10.12.17 - עלון לרופא 16.08.20 - עלון לרופא 22.12.23 - עלון לרופא 08.05.24 - עלון לרופא

עלון מידע לצרכן

04.08.16 - עלון לצרכן 10.12.17 - עלון לצרכן 16.08.20 - החמרה לעלון 13.05.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

פרופס

קישורים נוספים

RxList WebMD Drugs.com